17 results about "Carcinoembryonal antigen" patented technology

The invention belongs to the technical field of tumor vaccines, and particularly relates to an mRNA (messenger Ribonucleic Acid) vaccine for coding tumor antigen epitopes as well as a preparation method and application thereof. In order to overcome the defect of immune escape caused by insufficiency or loss of a single antigen, the invention provides an mRNA vaccine capable of simultaneously coding a plurality of tumor antigen epitopes, and the tumor antigen epitopes are selected from high-frequency mutation epitopes of human tumor driving genes, such as G12D, G12V and G12C mutations of RAS genes; the antigenic epitopes can be used for preparing antigenic epitopes related to common viruses of human tumors, such as HPV16E6 / E7, EBV LAMP1 or CMV pp65, and tumor high-expression carcino-embryonic antigen gene epitopes, such as MAGE-A4, NY-ESO-1, WT1, and the like. The mRNA vaccine is obtained by serially expressing a plurality of tumor antigen epitopes and encapsulating and delivering lipid nanoparticles. Experiments prove that the compound can effectively prevent and treat various tumors and has a wide application prospect.

The invention provides an application of a carcino-embryonic antigen related cell adhesion molecule 5 (CEACAM5) in treatment of pancreatic cancer. Research finds that a novel stem cell-like cluster cell subtype (hereinafter referred to as' stem cell-like TCs') is found, and the subtype is significantly related to poor prognosis of pancreatic ductal adenocarcinoma patients. Therefore, the invention provides a novel pancreatic ductal adenocarcinoma treatment medicine, namely the carcino-embryonic antigen related cell adhesion molecule 5, which has very positive significance on the treatment of the pancreatic ductal adenocarcinoma.

The invention provides a papillary thyroid carcinoma neck lymph node metastasis risk prediction method and system based on blood indexes and TI-RADS grading, and relates to the technical field of medical data analysis. According to the method, an original data set is constructed by obtaining TI-RADS classification, the maximum diameter of nodules, the number of nodules, gender, age and conventional hematology indexes including apolipoprotein B and carcino-embryonic antigen of a patient, characteristic variables are screened by adopting LASSO regression, and an independent prediction risk factor model is established in combination with multi-factor Logistic regression. And further constructing a column graph model, carrying out performance verification through multiple statistical indexes, and deploying the model to a webpage calculator based on a shiyapp to realize convenient output of the individualized risk probability. According to the method, efficient and accurate prediction of the preoperative lymph node metastasis risk is realized, and reliable decision support can be provided for clinic.

The preparation method comprises the following steps: immobilizing a specific capture antibody Ab1 of a carcino-embryonic antigen on the surface of a gold electrode, closing a non-specific site by bovine serum albumin to obtain a BSA / Ab1 / GE working electrode, capturing the carcino-embryonic antigen, fusing the carcino-embryonic antigen with an enzyme-coated HHOF-Ab2 nano probe, and detecting the enzyme-coated HHOF-Ab2 nano probe to obtain the sandwich type electrochemical immunosensor based on the enzyme-coated hydrogen bond organic framework hybrid catalyst. The enzyme coated HOF-based sandwich type electrochemical immunosensor is obtained; the sensor specifically recognizes CEA through 'Ab1-CEA-Ab2' double antibody sandwich, the cyclic reaction of H2O2 and HQ is catalyzed by virtue of the enzyme-coated HOF nanoprobe to amplify a signal, and finally chemical change caused by oxidizing hydroquinone into benzoquinone is converted into quantifiable current by virtue of an electrochemical workstation, so that ultra-sensitive detection of CEA is realized, and the sensor has the advantages of high sensitivity, high response speed, strong specificity and the like.

The invention relates to a gastric cancer evaluation system based on a platelet subcellular structure, comprising: a data acquisition module for acquiring a carcino-embryonic antigen level in a blood sample of a detected subject and a platelet proportion in which alpha particles are regularly distributed; the data analysis and judgment module is used for jointly calculating the risk score of the subject suffering from the gastric cancer according to the platelet proportion of'regular distribution 'of alpha particles and the carcino-embryonic antigen level; and the result output module is used for outputting a corresponding gastric cancer assessment result according to the risk score. According to the platelet proportion of'regular distribution 'of alpha particles in a blood sample of a subject and the carcino-embryonic antigen level, the risk score of the subject suffering from the gastric cancer is jointly calculated, the risk of the subject suffering from the gastric cancer is judged, the specificity is 87.5%, and the sensitivity is 87.5%.

The present invention relates to novel bispecific polypeptides, such as antibodies, and their use in the treatment of cancers, particularly cancers expressing carcinoembryonic antigen (CEA).

The invention belongs to the field of biology, and particularly relates to a chemiluminescence kit for detecting CEACAM1, a use method and application, the chemiluminescence kit comprises a streptavidin magnetic particle working solution, a biotinylated carcino-embryonic antigen related cell adhesion molecule 1 capture antibody solution and an acridinium ester labeled carcino-embryonic antigen related cell adhesion molecule 1 detection antibody solution. Coupling of acridinium ester and the antibody is efficient and simple, repeatability is good, large-scale production and application are easy, a biotin-avidin amplification system (BAS system) is used in a reaction system, quantitative detection of ultramicro markers is more sensitive and more efficient, and compared with a traditional enzyme-linked immunosorbent assay method, the method has the advantages that the detection sensitivity is high, and the sensitivity is high. The magnetic particle chemiluminescence reagent disclosed by the invention has the advantages of low cost, stable and reliable result, high test flux, convenience in production, small batch difference, easiness in large-scale application and the like.

The invention belongs to the technical field of biology, and particularly relates to a nano-enzyme for carcino-embryonic antigen detection. The nano-enzyme is iron-based monatomic nano-enzyme dFeSA, the dFeSA is Fe and N-doped amorphous carbon nano-particles, and Fe-N3-C is taken as a core and is combined with a carbon-based carrier with nitrogen vacancy and carbon defect. According to the present invention, the sensitivity is high, the detection limit is as low as 0.017 ng / mL, the detection range is wide, the stability is excellent, the anti-interference capability is excellent, and the carcino-embryonic antigen detection method has advantages of simple operation and low cost, and is suitable for early diagnosis and prognosis monitoring of cancers.

Pharmaceutical compositions comprising anti-CEACAM1mAb and their use in the inhibition of NET-mediated activity and in the prevention and treatment of pathologies associated with these activities are provided, and are exemplified by mAb CM24 that also exhibit effective inhibition of cancer cell migration and NET-induced platelet aggregation. Prognostic methods based on NET-biomarkers for use in patient selection and monitoring of therapeutic efficacy are also presented.

The invention relates to the technical field of early gastric cancer screening, and discloses a novel biomarker detection method for early gastric cancer screening, which comprises the following steps: S1, preparation before detection: performing joint detection on pepsinogen, gastritin-17, carcino-embryonic antigen and carbohydrate antigen 72-4, and preparing corresponding detection reagents and standard substances; s2, sample collection: adopting a disposable sterile blood taking needle and a vacuum tube, and extracting 3-5ml of venous blood through sterile operation; s3, sample treatment and storage: separating serum through a centrifugal machine, and after the treatment is completed, putting the sample into a storage device for storage; and S4, detection operation: preheating the detector, and then calibrating the detector by a standard product. In the invention, the pepsinogen, the gastritin-17, the carcino-embryonic antigen and the carbohydrate antigen 72-4 are jointly detected, so that the problem of low accuracy possibly caused by the fact that a marker detection method is mostly adopted in the existing early gastric cancer screening is solved.

The invention discloses a magnetic bead enrichment SERS (Surface Enhanced Raman Scattering) probe sensing platform based on lung cancer marker protein-DNA (Deoxyribose Nucleic Acid) signal conversion as well as a construction method and application of the magnetic bead enrichment SERS probe sensing platform. The target protein aptamer is an aptamer specifically bound with a carcino-embryonic antigen (CEA) protein; the SERS probe comprises gold nanoparticles, and the surfaces of the gold nanoparticles are covalently connected with a Raman reporter molecule sequence and capture DNA (Deoxyribose Nucleic Acid); the SERS probe is hybridized with the target protein aptamer on the first magnetic carrier compound by capturing DNA to form a DNA double-chain structure; the second magnetic carrier compound comprises a second magnetic carrier fixed with enriched DNA, and the enriched DNA sequence and the captured DNA are completely complementary. According to the invention, ultrasensitive and high-specificity quantitative detection of lung cancer marker protein (such as CEA) is realized.

The invention belongs to the technical field of plasma protein markers, and discloses a plasma protein marker and a risk prediction system for a heart failure onset risk of a type 2 diabetes mellitus patient, and the protein marker combination is applied to preparation of a kit for predicting the heart failure onset risk of the type 2 diabetes mellitus patient. The protein marker combination comprises a C-C motif chemotactic factor 24, a C-C motif chemotactic factor 7, a carcino-embryonic antigen related cell adhesion molecule 6, a fiber gelling protein 1, a follistatin, a polypeptide N-acetylgalactosamino transferase 5, an ADP ribosylation factor binding protein GGA1, a kallikrein 4, a nerve bundle protein, renin, a plasma protease C1 inhibitor and cardiac troponin I, the brain natriuretic peptide comprises a brain natriuretic peptide precursor, an N-terminal brain natriuretic peptide precursor, apolipoprotein C1, tetramer connexin, a Mepin A beta subunit and multi-ligand proteoglycan-4. The invention further constructs a risk score and prediction model for predicting the attack risk of the heart failure of the type 2 diabetes mellitus patient based on the protein marker.

The invention relates to a nano composite material which is prepared by the following steps: mixing layered Ti3C2 and an aqueous dispersion of graphene oxide, and then adding a reducing agent and an intercalator for hydrothermal reaction to obtain a Ti3C2 / Gr material; and mixing and stirring the Ti3C2 / Gr material with a UIO-66-NH2 aqueous dispersion, carrying out centrifugal separation, adding a methylene blue aqueous solution, stirring, carrying out centrifugal separation, cleaning, and drying the precipitate to obtain the MB-coated UIO-66-NH2 / Ti3C2 / Gr nano composite material. According to the method, an MB-coated UIO-66-NH2 / Ti3C2 / Gr composite material is taken as a substrate, a carcino-embryonic antigen aptamer is fixed on the surface of a modified electrode through EDC and NHS, and non-specific adsorption sites on the modified electrode are sealed by bovine serum albumin, so that an electrochemical sensing interface for detecting carcino-embryonic antigens is constructed. The electrochemical adaptive sensor has the characteristics of strong specificity, high sensitivity, low detection limit and the like, and has important scientific significance and application value for detection of tumor markers.

The present disclosure relates to anti-5T4 (5T4 carcino-embryonic antigen) antibodies, antigen binding fragments thereof, antibody drug conjugates (ADCs) derived therefrom, and uses thereof.

The present invention relates to compositions for detecting a lung cancer disease, comprising peptide affinity ligands for detecting different combinations of proteins of different groups of biomarkers which include CYFRA 21-1, Prolactin, Squamous Cell Carcinoma Antigen (SCC), Her2 / Neu, Cancer antigen 125 (CA125), carcinoembryonic antigen (CEA), C- reactive protein (CRP), Neuron Specific Enolase (NSE), C4 complement (C4), Interleukin 6 (IL-6), and Metallopeptidase Inhibitor 1 (TIMP-1). The invention further relates to methods of detecting or subtyping lung diseases, as well as to computer-implemented methods based on machine learning methods using expression data of the biomarkers.

The invention discloses a carcino-embryonic antigen detection kit based on magnetic bead-DNA self-assembly and SERS probe rapid response and a preparation method and application thereof, and belongs to the technical field of biological detection. The preparation method of the kit comprises the following steps: constructing a magnetic bead double-stranded DNA probe and a surface enhanced Raman scattering (SERS) probe; the target protein is combined with the aptamer, so that the protected DNA chain is dissociated, the conformation of the aptamer is opened, and the capture site is exposed. The site is hybridized with a captured DNA chain on the SERS probe, so that the SERS probe is connected to the magnetic bead. After the compound is enriched through magnetic separation, the Raman signal intensity is detected, so that accurate quantification of the target protein is realized. Through signal conversion and enrichment amplification, the method has the advantages of high sensitivity, high specificity and quick response.

The invention discloses a pair of carcino-embryonic antigen monoclonal antibody hybridoma cell strains and a carcino-embryonic antigen detection method, and belongs to the technical field of biological detection. Specifically, CEA protein is used for immunizing mice, and a series of cells with high titer (gt; the method comprises the following steps: firstly, preparing a series of antibodies (1, 10 million), pairing the series of antibodies by a chessboard method, selecting antibody pairs with the best detection effect, namely antibodies 31-11 and antibodies 46-44, and preserving hybridoma cell strains secreting the two antibodies, namely hybridoma cell strains CEA31-11 and hybridoma cell strains CEA46-44 with the preservation numbers of CCTCC No.202547 and CCTCC No.202548. According to the invention, the hybridoma cell strains CEA31-11 and CEA46-44 secreting the two antibodies can be used for preparing the hybridoma cell strains CEA31-11 and CEA46-44 with the preservation number of CCTCC No.202547. The CEA detection method constructed by the two antibodies can effectively assist in screening, diagnosis, curative effect evaluation and relapse monitoring of cancers.